A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: November 17, 2010
Last updated: January 17, 2013
Last verified: January 2013

The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).

Condition Intervention Phase
Smoking Cessation
Drug: Varenicline
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Continuous Abstinence Rate for Weeks 9-12 (CAR 9-12) [ Time Frame: Weeks 9-12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Continuous Abstinence Rate Weeks 9-52 (CAR 9-52) [ Time Frame: Weeks 9-52 ] [ Designated as safety issue: No ]
  • Continuous Abstinence Rate Weeks 9-24 (CAR 9-24) [ Time Frame: Weeks 9-24 ] [ Designated as safety issue: No ]
  • 7 day point prevalence of smoking cessation at Weeks 12, 24 and 52 [ Time Frame: Weeks 12, 24 and 52 ] [ Designated as safety issue: No ]

Enrollment: 498
Study Start Date: December 2010
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Varenicline Drug: Varenicline
Varenicline 1mg twice daily
Placebo Comparator: Placebo Drug: Placebo
Matched placebo twice daily


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Smokers aged 18 years or above and wanting to stop smoking
  • Smokers who have smoked an average of at least 10 cigarettes per day over the last 4 weeks
  • Smokers who have tried before to stop smoking at least once with varenicline, and who took varenicline for at least 2 weeks
  • The last attempt to stop smoking must be at least 3 months before entering the study

Exclusion Criteria:

  • Individuals who have not tolerated varenicline well previously, or who have a current or prior medical or psychiatric history that would make entry into the trial inadvisable
  • Individuals who have previously participated in clinical trials of varenicline
  • Individuals who have been participating in another smoking cessation trial within the last 3 months, or other drug trial within the last 30 days
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01244061

  Show 37 Study Locations
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01244061     History of Changes
Other Study ID Numbers: A3051139
Study First Received: November 17, 2010
Last Updated: January 17, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 17, 2014